^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1121P - Prognostic value of soluble transforming growth factor-ß and soluble programmed death-ligand 1 in patients with non-functioning neuroendocrine tumors or pheochromocytomas/paragangliomas
Published date:
09/13/2021
Excerpt:
The study population consisted of 34 patients who received everolimus as a systemic treatment for non-functioning NETs, pheochromocytoma, or extra-adrenal paragangliomas....Patients with low sTGF-β level (<26.12 ng/mL) at baseline showed better progression-free survival (PFS) than those with high sTGF-β level (22.73 months vs. 12.97 months, p=0.019). Similarly, patients with low sPD-L1 level (<6.65 ng/mL) at baseline tended to have longer PFS than patients with high sPD-L1 level (18.97 months vs. 7.37 months, p=0.095).
